Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.39 |
| ▸ | PTAFR | P25105 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | GRK2 | P25098 | 1/20 | 0.33 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7073312 | 0.84 | TRPV1 (0.37) | GAAACSS2 | |
| SCHEMBL7073496 | 0.83 | NPC1 (0.46) | NAMPTSMN1; SMN2ACSS2 | |
| SCHEMBL7072326 | 0.82 | TPSAB1 (0.41) | SMN1; SMN2 | |
| SCHEMBL7072285 | 0.82 | SMN1; SMN2 (0.40) | SMN1; SMN2 | |
| SCHEMBL7071920 | 0.82 | MAPT (0.35) | GAAACSS2 | |
| SCHEMBL7072504 | 0.82 | GAA (0.38) | SMN1; SMN2GAAACSS2 | |
| SCHEMBL7074863 | 0.82 | GAA (0.36) | NAMPTSMN1; SMN2GAAACSS2 | |
| SCHEMBL7075212 | 0.82 | NPC1 (0.43) | TSHR | |
| SCHEMBL7072576 | 0.82 | GAA (0.37) | SMN1; SMN2GAAACSS2 | |
| SCHEMBL7075741 | 0.81 | TGM2 (0.38) | SMN1; SMN2TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | US | disclosed |
| US-6562854-B2 | Antiinflammatory agents; respiratory system disorders | AXYS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | NAMPT 1724/4885PTAFR 585/4885TBXAS1 817/4885 |
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | CMA1, TPSG1, TPSD1 | NAMPT 1469/4885PTAFR 1174/4885TBXAS1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.